ClinicalTrials.gg
CompletedNCT02218684Updated Aug 18, 2014

Tolerability and Pharmacokinetics of Telmisartan in Combination With Lacidipine in Healthy Male Subjects

A Phase 1 interventional study of Telmisartan and Lacidipine in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-18.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The trial objectives were to investigate the tolerability and pharmacokinetics of 80 mg telmisartan and 2, 4 or 6 mg lacidipine administered concurrently.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male caucasian subjects as determined by results of screening
  • Written in accordance with Good Clinical Practice and local legislation given
  • Age >= 18 and \<= 50 years
  • Broca >= -20% and \<= + 20%

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination (including blood pressure, pulse rate and (ECG) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of gastrointestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurologic disorders
  • History of orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (> 24 hours) (\<= 1 month prior to administration or during the trial)
  • Use of any drugs which might influence the results of the trial (\<= 10 days prior to administration or during the trial)
  • Participation in another trial with an drug (\<= 2 months prior to administration or during the trial)
  • Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Inability to refrain from smoking on study days
  • Alcohol abuse (> 60g/day)
  • Drug abuse
  • Blood donation > 100 ml (\<= 4 weeks prior to administration or during the trial)
  • Excessive physical activities (\<= 10 days prior to administration or during the trial)
  • Any laboratory value outside the reference range of clinical relevance
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Telmisartan + Lacidipine - low dose

    Drug: Telmisartan · Drug: Lacidipine

  • Experimental
    Telmisartan + Lacidipine - medium dose

    Drug: Telmisartan · Drug: Lacidipine

  • Experimental
    Telmisartan + Lacidipine - high dose

    Drug: Telmisartan · Drug: Lacidipine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum measured concentration of the analyte in plasma)

    Time frame: up to 72 hours after drug administration

  2. Number of subjects with adverse events

    Time frame: up to 72 hours after drug administration

Secondary outcomes

  1. AUC (Area under the concentration-time curve of the analyte in plasma)

    Time frame: up to 72 hours after drug administration

  2. tmax (Time from dosing to the maximum concentration of the analyte in plasma)

    Time frame: up to 72 hours after drug administration

  3. CL/F (Apparent clearance of the analyte in plasma following extravascular administration)

    Time frame: up to 72 hours after drug administration

  4. Vz/F (Apparent volume of distribution of the analyte during the terminal phase)

    Time frame: up to 72 hours after drug administration

  5. MRT (Mean residence time of the analyte in the body)

    Time frame: up to 72 hours after drug administration

  6. t½ (Terminal half-life of the analyte in plasma)

    Time frame: up to 72 hours after drug administration

  7. Number of subjects with abnormal changes in laboratory parameters

    Time frame: up to 72 hours after drug administration

  8. Number of subjects with clinically significant changes in vital signs

    Time frame: up to 72 hours after drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 1998 and a primary completion of Nov 1998. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2014
First posted
Aug 18, 2014
Start
Sep 1998
Primary completionActual
Nov 1998
Last update
Aug 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02218684
Responsible party
Sponsor
First posted
Aug 18, 2014
Start date
Sep 1998
Primary completion
Nov 1998
Last update
Aug 18, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Lacidipine

Start the discussion